Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late

Digestive and Liver Disease

Volumn 46, Issue 10, 2014, Pages 923-927

  Pellicelli, Adriano M ^a   Montalbano, Marzia ^b   Lionetti, Raffaella ^b   Durand, Christine ^c   Ferenci, Peter ^d   D'Offizi, Gianpiero ^b   Knop, Viola ^e   Telese, Andrea ^f   Lenci, Ilaria ^f   Andreoli, Arnaldo ^a   Zeuzem, Stefan ^e   Angelico, Mario ^f  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cholestatic hepatitis; Cirrhosis; Daclatasvir; Direct antiviral agents; Disease recurrence; HCV; MELD; Sofosbuvir

Indexed keywords

ALBUMIN; CORTICOSTEROID; CYCLOSPORIN; DACLATASVIR; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; URIDINE PHOSPHATE;

ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CHILD PUGH SCORE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COMPASSIONATE USE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FASCIITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; SEPTIC SHOCK; SERUM; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; COMPASSIONATE USE TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84920941109     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.06.004     Document Type: Article

References (15)

1. Adam R., McMaster P., O'Grady J.G., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transplantation 2003, 9:1231-1243.
2. Kim W.R. The burden of hepatitis C in the United States. Hepatology 2002, 36:S30-S34.
3. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transplantation 2008, 14(Suppl. 2):S36-S44.
4. Berenguer M., Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. Journal of Hepatology 2013, 58:1028-1041.
5. Narang T.K., Ahrens W., Russo M.W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transplantation 2010, 16:1228-1235.
6. Gurusamy K., Osmani B., Xirouchakis E., et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database of Systematic Reviews 2010, CD006803.
7. Coilly A., Roche B., Dumortier J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Journal of Hepatology 2014, 60:78-86.
8. Forns X., Prieto M., Charlton M.M., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. Journal of Hepatology 2014, 60(Suppl. 1):S26.
9. Charlton M.R., Gane E.J., Manns M.P., et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology 2013, 58:1378A.
10. Sulkowski M.D., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 2014, 370:211-221.
11. Pol S., Ghalib R., Rustgi V.K., et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infectious Diseases 2012, 12:671-677.
12. Fontana R., Hughes E., Bifano M., et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. American Journal of Transplantation 2013, 13:1601-1605.
13. Bedossa P., Poynard T. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996, 24:289-293. The French METAVIR Cooperative Study Group.
14. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine 1999, 130:461-470.
15. Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events 2004, National Institute of Allergy and Infectious Diseases, Bethesda, MD. http://rsc.techres.com/Document/safetyandpharmacovigilance/TableforGradingSeverityofAdultPediatricAdverseEvents.pdf.